Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 13/20 | 0.37 |
| ▸ | AHCY | P23526 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654867 | 1.00 | NT5E (0.37) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL21777024 | 1.00 | NT5E (0.37) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL28695306 | 0.95 | NT5E (0.36) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL28695303 | 0.95 | NT5E (0.36) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL28695304 | 0.95 | NT5E (0.36) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL21776912 | 0.92 | NT5E (0.37) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL21776915 | 0.92 | NT5E (0.37) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL29654863 | 0.91 | NT5E (0.35) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL23042454 | 0.91 | NT5E (0.34) | NT5EAHCYADORA3ADORA2AADORA2B | |
| SCHEMBL29654875 | 0.91 | NT5E (0.33) | NT5EADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220117993-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| US-20210323993-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-10-21 | — | — | US | disclosed |
| US-20200407393-A1 | Medical Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | NT5E 1408/4885AHCY 1161/4885ADORA3 1498/4885 |
| US-20210323993-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, LSS | NT5E 1285/4885AHCY 1313/4885ADORA3 1043/4885 |
| US-20220117993-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, ABCB1 | NT5E 1640/4885AHCY 1582/4885ADORA3 1885/4885 |
| US-20200407393-A1 | Medical Use | ABCB11, SLC10A1, SLC10A2 | NT5E 1129/4885AHCY 3793/4885ADORA3 454/4885 |
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, NFATC1 | NT5E 1279/4885AHCY 3003/4885ADORA3 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.